Veraxa Biotech reports positive in vitro proof-of-concept for antibody-oligonucleotide conjugate candidate with Secarna

• Veraxa Biotech reported positive early in vitro results from its AOC research alliance with Secarna Pharmaceuticals.
• An AOC candidate showed higher potency than the equivalent unconjugated oligonucleotide, supporting targeted antibody-guided delivery.
• The collaboration targets next-generation AOCs for autoimmune disease and chronic immune conditions, expanding beyond Veraxa’s core solid-tumor focus.
• Partners began talks on next steps following the proof-of-concept milestone achieved in under a year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-009237), on August 24, 2026, and is solely responsible for the information contained therein.